Review

Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials

Sandra J. Hamilton¹, Gerald F. Watts²

Manuscript submitted March 20, 2013; resubmitted June 19, 2013; accepted June 19, 2013.

Keywords: atherogenic dyslipidemia, clinical trials, pharmacotherapy, type 2 diabetes, fatty acid, lipoprotein, HDL cholesterol

Abstract

Patients with type 2 diabetes (T2D) are at a markedly increased risk of cardiovascular disease (CVD). Dyslipidemia is a common risk factor and a strong predictor of CVD in T2D patients. Although statins decrease the incidence of CVD in T2D, residual cardiovascular risk remains high despite the achievement of optimal or near-optimal plasma low-density lipoprotein (LDL) cholesterol concentrations. This may, in part, be due to uncorrected atherogenic dyslipidemia. Hypertriglyceridemia, the driving force behind diabetic dyslipidemia, results from hepatic overproduction and/or delayed clearance of triglyceride-rich lipoproteins. In patients treated with a statin to LDL-cholesterol goals, the addition of ezetimibe, fenofibrate, niacin, or n-3 fatty acid ethyl esters may be required to correct the persistent atherogenic dyslipidemia. Clinical trial evidence describing best practice is limited, but recent data supports the strategy of adding fenofibrate to a statin, and suggests specific benefits in dyslipidemic patients and in the improvement of diabetic retinopathy. However, based on results from a recent clinical trial, niacin should not be added to a statin in individuals with low high-density lipoprotein cholesterol and very well controlled LDL-cholesterol. Further evidence is required to support the role of ezetimibe and n-3 fatty acids in treating residual CVD risk in statin-treated T2D patients.

Fulltext: HTML , PDF (252KB)

This article has been cited by other articles:

	Dyslipidemia in diabetes mellitus and cardiovascular disease Warraich HJ, Rana JS Cardiovasc Endocrinol 2017. 6(1):27-32
	The Atherogenic Dyslipidemia Ratio Log (Tg)/Hdl-C Was Not Associated with Urinary Albumin Excretion Rate (Uaer) and Increased Cardiovascular Risk in Black Patients with Type 2 Diabetes Kajingulu MF, Lepira BF, Mbutiwi IN, Makulo JR, Bieleli E, Nseka MN World J Cardiovasc Dis 2016. 6(1):14-20
	Role for combination therapy in diabetic dyslipidemia Warraich HJ, Wong ND, Rana JS Curr Cardiol Rep 2015. 17(5):589
	Targeting metabolic disorders by natural products Tabatabaei-Malazy O, Larijani B, Abdollahi M J Diabetes Metab Disord 2015. 14:57
	Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine Seto SW, Yang GY, Kiat H, Bensoussan A, Kwan YW, Chang D Int J Endocrinol 2015. 2015:810439
	Origin and therapy for hypertriglyceridaemia in type 2 diabetes Pang J, Chan DC, Watts GF World J Diabetes 2014. 5(2):165-175